189 related articles for article (PubMed ID: 30585088)
21. A comprehensive procedure for antiviral inhibitor discovery using EV71 as an example.
Cao L; Zhu S; Wang Y; Lou Z; Sun Y
Biophys Rep; 2015; 1():81-89. PubMed ID: 26942222
[TBL] [Abstract][Full Text] [Related]
22. The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases.
Mohammadi Pour P; Fakhri S; Asgary S; Farzaei MH; Echeverría J
Front Pharmacol; 2019; 10():1207. PubMed ID: 31787892
[TBL] [Abstract][Full Text] [Related]
23. Current landscape and future prospects of antiviral drugs derived from microbial products.
Takizawa N; Yamasaki M
J Antibiot (Tokyo); 2017 Oct; 71(1):45-52. PubMed ID: 29018267
[TBL] [Abstract][Full Text] [Related]
24. Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins.
Hangyu W; Panpan L; Jie S; Hongyan W; Linmiao W; Kangning H; Yichen S; Shuai W; Cheng W
J Microbiol Biotechnol; 2024 Apr; 34(7):1376-1384. PubMed ID: 38934770
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.
Kamzeeva PN; Aralov AV; Alferova VA; Korshun VA
Curr Issues Mol Biol; 2023 Aug; 45(8):6851-6879. PubMed ID: 37623252
[TBL] [Abstract][Full Text] [Related]
26. virusMED: an atlas of hotspots of viral proteins.
Zhang H; Chen P; Ma H; Woińska M; Liu D; Cooper DR; Peng G; Peng Y; Deng L; Minor W; Zheng H
IUCrJ; 2021 Sep; 8(Pt 6):931-42. PubMed ID: 34614039
[TBL] [Abstract][Full Text] [Related]
27. virusMED: your travel guide to the virus world.
Coulibaly F
IUCrJ; 2021 Nov; 8(Pt 6):857-859. PubMed ID: 34804539
[TBL] [Abstract][Full Text] [Related]
28. Retraction for Li et al., "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs".
Li Y; Huo S; Yin Z; Tian Z; Huang F; Liu P; Liu Y; Yu F
mBio; 2024 Apr; 15(4):e0010624. PubMed ID: 38517163
[No Abstract] [Full Text] [Related]
29. The PA Subunit of the Influenza Virus Polymerase Complex Affects Replication and Airborne Transmission of the H9N2 Subtype Avian Influenza Virus.
Hao M; Han S; Meng D; Li R; Lin J; Wang M; Zhou T; Chai T
Viruses; 2019 Jan; 11(1):. PubMed ID: 30634394
[TBL] [Abstract][Full Text] [Related]
30. Development of a Universal Influenza Vaccine.
Estrada LD; Schultz-Cherry S
J Immunol; 2019 Jan; 202(2):392-398. PubMed ID: 30617121
[TBL] [Abstract][Full Text] [Related]
31. A novel linear epitope crossing Group 1 and Group 2 influenza A viruses located in the helix A of HA2 derived from H7N9.
Li Z; Wan Z; Li T; Xie Q; Sun H; Chen H; Liang G; Shao H; Qin A; Ye J
Vet Microbiol; 2019 Jan; 228():39-44. PubMed ID: 30593378
[TBL] [Abstract][Full Text] [Related]
32. In Silico Design of New Inhibitors Against Hemagglutinin of Influenza.
Perrier A; Eluard M; Petitjean M; Vanet A
J Phys Chem B; 2019 Jan; 123(3):582-592. PubMed ID: 30590925
[TBL] [Abstract][Full Text] [Related]
33. Baloxavir marboxil (Xofluza) for treatment of influenza.
Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474
[No Abstract] [Full Text] [Related]
34. Interplay between Influenza Virus and the Host RNA Polymerase II Transcriptional Machinery.
Walker AP; Fodor E
Trends Microbiol; 2019 May; 27(5):398-407. PubMed ID: 30642766
[TBL] [Abstract][Full Text] [Related]
35. Multiple amino acid substitutions involved in the adaption of three avian-origin H7N9 influenza viruses in mice.
Qin J; Peng O; Shen X; Gong L; Xue C; Cao Y
Virol J; 2019 Jan; 16(1):3. PubMed ID: 30621708
[TBL] [Abstract][Full Text] [Related]
36. Host and Viral Proteins Modulating Ebola and Marburg Virus Egress.
Gordon TB; Hayward JA; Marsh GA; Baker ML; Tachedjian G
Viruses; 2019 Jan; 11(1):. PubMed ID: 30609802
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Ongoing Influenza A Virus Replication Reveals Different Mechanisms of RIG-I Activation.
Liu G; Lu Y; Liu Q; Zhou Y
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602605
[TBL] [Abstract][Full Text] [Related]
38. Generation of highly productive and mammalian nonpathogenic recombinant H9N2 avian influenza viruses by optimization of 3'end promoter and NS genome.
An SH; Lee CY; Choi JG; Lee YJ; Kim JH; Kwon HJ
Vet Microbiol; 2019 Jan; 228():213-218. PubMed ID: 30593370
[TBL] [Abstract][Full Text] [Related]
39. Clinical indices and mortality of hospitalized avian influenza A (H7N9) patients in Guangdong, China.
Yang Y; Li X; Birkhead GS; Zheng Z; Lu JH
Chin Med J (Engl); 2019 Feb; 132(3):302-310. PubMed ID: 30681496
[TBL] [Abstract][Full Text] [Related]
40. The interaction of cellular protein ANP32A with influenza A virus polymerase component PB2 promotes vRNA synthesis.
Wei X; Liu Z; Wang J; Yang R; Yang J; Guo Y; Tan H; Chen H; Liu Q; Liu L
Arch Virol; 2019 Mar; 164(3):787-798. PubMed ID: 30666459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
